Objective：To investigate the efficacy and safety of Baofukang suppository on the basis of recombinant human interferon α-2b in the treatment of high-risk human papillomavirus (HR-HPV) infection. Methods： 80 HR-HPV patients were randomly divided into 2 groups. The control group (40 cases) was treated with recombinant human interferon α-2b vaginal effervescent capsule. The observation group (40 cases) was treated with Baofukang suppository on the basis of recombinant human interferon α-2b vaginal effervescent capsule. Both groups were treated for 3 months. The treatment effects of the two groups were compared.The duration of abnormal secretions, HPV viral load, TCT test results and cervical inflammation scores of the two groups were recorded, and the adverse reactions were observed. Results： Compared with the control group (75.00%), the total effective rate of the observation group (95.00%) was higher (P<0.05). The duration of abnormal secretions in the observation group was (14.47±3.15) d, comparing with the control group (20.12±3.89) d, shows significantly shorter (P<0.05). After treatment, the normal rate of TCT in the two groups was significantly higher than that before treatment (P<0.05 ), and the normal rate of TCT in the observation group was higher than that in the control group(P<0.05). After treatment, the HPV viral load in the observation group decreased comparing with the control group (P<0.05), and the cervical inflammation score decreased (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion： Baofukang suppository based on recombinant human interferon α-2b vaginal effervescent capsule is effective and safe in the treatment of HRHPV infection.